Top Dividend ETF Expansion: Frontage Grows Operations in Canada

Highlights

• Frontage Holdings Corporation has expanded its Canadian operations by appointing Dr. Abdul Mutlib as President of Frontage Laboratories, Canada.
• The expansion focuses on strengthening the company’s role in the biotechnology and pharmaceutical research sector across Toronto and Vancouver.
• The move supports Canada's growing life sciences ecosystem and reflects Frontage's global service strategy.

Frontage Holdings Corporation, a global Contract Research Organization (CRO), has announced the expansion of its pharmaceutical operations in Canada. The initiative strengthens its position in the biotech and drug development sector, aligning with broader industry movements tracked by indexes such as the S&P/TSX Capped Health Care Index. As pharmaceutical services continue to gain traction in public markets, including those reflected in the top dividend ETF segment, global CROs like Frontage are enhancing their geographic reach and service offerings.

Leadership Expansion Across Toronto and Vancouver

As part of the strategic expansion, Dr. Abdul Mutlib has been appointed as President of Frontage Laboratories, Canada. He will lead the company’s Canadian operations while also serving as the Chief Scientific & Strategy Officer for Frontage Laboratories globally. This dual role enables Dr. Mutlib to ensure operational continuity and support the company’s scientific and strategic alignment with market demands.

Dr. Mutlib will be responsible for overseeing sites located in Toronto and Vancouver, both emerging centers for pharmaceutical innovation and clinical research. He will report directly to Dr. Wentao Zhang, Co-Chief Executive Officer of Frontage. This leadership change reflects the company’s intent to deliver high-quality, science-led solutions across new geographies.

Strengthening Presence in Canada’s Biotech Industry

Canada's life sciences industry continues to grow steadily, backed by a supportive regulatory framework and an increasing number of biopharma startups. Toronto and Vancouver, in particular, have witnessed strong growth in biotech-related R&D activity. Frontage’s expansion aligns with this growth trend, offering integrated services to pharmaceutical clients seeking localized and efficient research support.

According to Frontage leadership, the expansion is part of a broader strategic framework aimed at global service integration. Dr. Zhang acknowledged Dr. Mutlib’s longstanding contributions and highlighted his role in accelerating the company’s capabilities in Canada, a market known for innovation in clinical trial development, regulatory services, and bioanalytical testing.

Comprehensive Research Services for Biopharmaceutical Development

Frontage Holdings provides end-to-end services across the entire pharmaceutical development lifecycle. These include:

• Drug metabolism and pharmacokinetics (DMPK)

• Analytical testing and formulation development

• Clinical and preclinical trial material manufacturing

• Bioanalysis

• Toxicology assessments and early-phase clinical studies

By offering a full spectrum of services, Frontage allows clients to streamline development timelines and improve regulatory outcomes. The expansion of these services into Canada enables the company to meet the increasing demand from biotech firms for localized support and access to global scientific resources.

Vision for R&D Collaboration and Growth

Dr. Mutlib expressed strong confidence in Frontage’s Canadian team and outlined a vision to expand the company’s local footprint. His focus includes deepening collaborations with Canadian agencies and institutions to support the national goal of becoming a leading global center for biotechnology and pharmaceutical innovation.

This initiative underscores Frontage’s aim to serve as a long-term R&D partner for Canadian and international pharmaceutical companies. The leadership believes that integrating local expertise with global infrastructure will create a scalable, science-based platform for continuous service enhancement.

Global Alignment and Client-Focused Expansion Strategy

Frontage Holdings operates through its global subsidiaries, delivering specialized services to clients from the early discovery phase through to late-stage clinical development. The organization’s strategy emphasizes scientific integrity, regulatory compliance, and client-specific project management.

With a growing presence in North America and an expanding footprint in Asia and Europe, Frontage is positioning itself as a key provider in the outsourced pharmaceutical development market. The Canadian expansion is a reflection of this global approach and adds to the company's existing capabilities in the region.

As the broader biotechnology sector continues to intersect with public markets and equity products, the evolution of global CROs like Frontage supports long-term service demand across financial and research ecosystems. This includes sectors highlighted by the top dividend ETF universe, where pharmaceutical and healthcare companies form a stable component.

By enhancing its service network in Canada through strategic leadership and comprehensive R&D capabilities, Frontage Holdings Corporation reinforces its commitment to global collaboration in pharmaceutical development.